|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Fumapharm_AG
gptkb:Acorda_Therapeutics
gptkb:CureVac_AG
gptkb:Elan_Corporation
gptkb:Sangamo_Therapeutics
gptkb:Syntimmune
gptkb:Tysabri
gptkb:Nightstar_Therapeutics
Conforma Therapeutics
Cambridge_Antibody_Technology
Neurimmune_AG
Aducanumab_from_Neurimmune_AG
AstraZeneca's_neuroscience_portfolio
Gene_Therapies_Inc.
Tysabri_from_Elan_Corporation
Zolgensma_from_AveXis
|
|
gptkbp:CEO
|
gptkb:Christopher_A._Viehbacher
|
|
gptkbp:clinicalTrials
|
ongoing
|
|
gptkbp:employeeCount
|
approximately 7,000
|
|
gptkbp:focus
|
neurology
|
|
gptkbp:founded
|
1985
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BIIB
|
|
gptkbp:is_part_of
|
gptkb:NASDAQ-100
S&P 500
NASDAQ_Biotechnology_Index
|
|
gptkbp:market
|
approximately $20 billion
|
|
gptkbp:operates_in
|
Michael_Ehlers
|
|
gptkbp:partnerships
|
gptkb:Samsung_Bioepis
gptkb:Ionis_Pharmaceuticals
|
|
gptkbp:products
|
gptkb:Tecfidera
gptkb:Plegridy
gptkb:Spinraza
gptkb:Avonex
Zolgensma
Aducanumab
|
|
gptkbp:research
|
Alfred_Sandrock
|
|
gptkbp:research_focus
|
Alzheimer's disease
Parkinson's disease
multiple sclerosis
spinal muscular atrophy
|
|
gptkbp:stockExchange
|
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Biogen_Idec
Biogen_International_GmbH
Biogen_MA_Inc.
|
|
gptkbp:website
|
www.biogen.com
|